Sarepta Therapeutics’ (SRPT) Sell Rating Reiterated at HC Wainwright

HC Wainwright restated their sell rating on shares of Sarepta Therapeutics (NASDAQ:SRPT) in a report released on Thursday morning,Benzinga reports.

A number of other brokerages have also recently commented on SRPT. Wedbush lifted their target price on Sarepta Therapeutics from $29.00 to $35.00 and gave the stock an “outperform” rating in a report on Thursday, March 26th. Weiss Ratings restated a “sell (d)” rating on shares of Sarepta Therapeutics in a report on Monday, December 29th. Needham & Company LLC restated an “underperform” rating on shares of Sarepta Therapeutics in a research report on Thursday, March 26th. Oppenheimer reaffirmed an “outperform” rating and set a $37.00 price objective on shares of Sarepta Therapeutics in a research note on Thursday, March 19th. Finally, Barclays initiated coverage on shares of Sarepta Therapeutics in a research note on Wednesday, January 28th. They issued an “equal weight” rating and a $20.00 target price on the stock. Nine investment analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and six have given a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $32.63.

Sarepta Therapeutics Stock Up 1.8%

Shares of NASDAQ SRPT opened at $21.55 on Thursday. The firm’s 50-day moving average price is $19.08 and its 200-day moving average price is $20.43. The company has a current ratio of 2.32, a quick ratio of 1.48 and a debt-to-equity ratio of 0.73. The stock has a market capitalization of $2.26 billion, a price-to-earnings ratio of -2.55, a P/E/G ratio of 0.30 and a beta of 0.29. Sarepta Therapeutics has a 12-month low of $10.41 and a 12-month high of $64.80.

Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported ($3.58) EPS for the quarter, missing the consensus estimate of ($0.87) by ($2.71). Sarepta Therapeutics had a negative return on equity of 50.74% and a negative net margin of 38.34%.The company had revenue of $442.93 million during the quarter, compared to analysts’ expectations of $390.95 million. During the same quarter in the prior year, the business posted $1.90 EPS. The company’s revenue was down 32.7% on a year-over-year basis. On average, equities research analysts anticipate that Sarepta Therapeutics will post 2.67 EPS for the current fiscal year.

Insider Buying and Selling

In other news, Director Stephen Mayo sold 7,239 shares of the firm’s stock in a transaction that occurred on Thursday, March 12th. The shares were sold at an average price of $17.02, for a total transaction of $123,207.78. Following the transaction, the director directly owned 1,765 shares of the company’s stock, valued at approximately $30,040.30. This trade represents a 80.40% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 7.60% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of SRPT. CWM LLC lifted its holdings in shares of Sarepta Therapeutics by 4,033.3% in the 3rd quarter. CWM LLC now owns 72,705 shares of the biotechnology company’s stock worth $1,401,000 after buying an additional 70,946 shares during the period. Aberdeen Group plc raised its holdings in shares of Sarepta Therapeutics by 59.6% in the third quarter. Aberdeen Group plc now owns 1,982,764 shares of the biotechnology company’s stock valued at $38,208,000 after acquiring an additional 740,360 shares in the last quarter. Boxer Capital Management LLC raised its holdings in shares of Sarepta Therapeutics by 900.0% in the third quarter. Boxer Capital Management LLC now owns 250,000 shares of the biotechnology company’s stock valued at $4,818,000 after acquiring an additional 225,000 shares in the last quarter. Mirador Capital Partners LP purchased a new stake in Sarepta Therapeutics in the fourth quarter worth about $3,012,000. Finally, Wealth Enhancement Advisory Services LLC lifted its stake in Sarepta Therapeutics by 143.9% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 106,759 shares of the biotechnology company’s stock worth $2,410,000 after acquiring an additional 62,981 shares during the period. Institutional investors own 86.68% of the company’s stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.